INVO Fertility (IVF) Stock News, Apr-Jun 2025

INVO Fertility (NASDAQ: IVF) has expanded telehealth capabilities at its Wisconsin Fertility Institute center to enhance access to fertility care. Dr. Gretchen Collins, medical director and fertility specialist, has obtained additional licenses in nine states including Illinois, Minnesota, Iowa, Montana, Colorado, Georgia, Alabama, Kansas, and Indiana. The telehealth platform enables virtual consultations, personalized fertility assessments, treatment planning, and ongoing support. While consultations and planning can be done remotely, critical procedures like egg retrievals and embryo transfers will continue to be performed at the clinic's physical location. This expansion aims to serve patients in rural and underserved areas, making specialized fertility care more accessible while maintaining high-quality in-person treatment standards.

INVO Fertility's Wisconsin Fertility Institute clinic has been named to Newsweek's America's Best Fertility Clinics for 2025. The prestigious recognition was based on four key criteria: CDC-published ART quality metrics, a nationwide survey of fertility specialists and medical professionals, accreditation data from major healthcare organizations (JCI, CAP, CLIA, AIUM), and patient satisfaction through Google reviews. The ranking, compiled in partnership with Statista, evaluates top facilities designated as fertility clinics and advanced reproductive technologies providers by the CDC.

INVO Fertility (NASDAQ: IVF), a healthcare services company focused on expanding access to advanced fertility treatments, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The company will engage in a virtual webcast fireside chat at 4:15 p.m. ET and conduct one-on-one meetings with investors throughout the event.

The webcast will be accessible through the conference homepage and will be available for replay after the event. Investors interested in one-on-one meetings with management can arrange them through Lytham Partners or by registering for the event directly on their website.

INVO Fertility (NASDAQ: IVF) reported its Q1 2025 financial results, marked by modest revenue growth and a strategic shift to focus exclusively on fertility operations. The company's revenue increased 4% to $1.64 million compared to Q1 2024. Consolidated clinic revenue from Atlanta and Madison locations grew 5% to $1.62 million. However, the company reported a significant net loss of $(17.4) million, largely due to a $14.6 million non-cash impairment charge related to NAYA Therapeutics assets. In April 2025, INVO announced plans to divest a majority stake in NAYA Therapeutics while maintaining a minority position for potential upside. The company is implementing growth initiatives at existing clinics and exploring expansion through acquisitions, aiming to achieve cash flow break-even and profitability.

INVO Fertility reported strong financial results for 2024, achieving a remarkable 116% annual revenue growth to $6.5 million. The company's Q4 2024 revenue reached $1.69 million, up 22% year-over-year.

Key highlights include a 125% increase in consolidated clinic revenue to $6.45 million and a 78% rise in total clinic revenue to $7.73 million. Despite these gains, the company recorded a net loss of $9.1 million, largely due to NAYA Therapeutics merger costs. However, Adjusted EBITDA improved significantly to $(2.2) million from $(4.9) million in 2023.

The company announced plans to divest its majority stake in NAYA Therapeutics to refocus on its core fertility operations. With three operating fertility centers in Wisconsin, Georgia, and Alabama, INVO aims to expand into additional markets, capitalizing on declining U.S. fertility rates and increasing demand for assisted reproductive technologies.